Johnson & Johnson CFO Exercises Options and Sells 16,820 Shares on 08/15/2025
Rhea-AI Filing Summary
Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (JNJ), reported transactions dated 08/15/2025. He exercised 16,820 employee stock options at an exercise price of $101.87 and simultaneously sold 16,820 common shares at a weighted-average sale price of $176.9067 (trades ranged $176.87–$177.015). After these transactions his direct beneficial ownership is reported as 14,000 shares. He also holds 68,835 shares indirectly via a spousal lifetime access trust (SLAT) and 2,145 shares indirectly through the Johnson & Johnson 401(k) stock fund. The form was signed by an attorney-in-fact on 08/18/2025.
Positive
- Timely disclosure of option exercise and sale under Section 16 with a signed filing
- Detailed pricing disclosure including weighted-average sale price and range ($176.87–$177.015)
- Clear identification of indirect holdings via SLAT and the 401(k) plan
Negative
- Reduction in direct holdings to 14,000 shares following the transactions
- Large insider sale of 16,820 shares on a single day (08/15/2025) which may reduce insider-held liquid shares
Insights
TL;DR: Routine option exercise and concurrent sale; results in modest net direct holdings and unchanged indirect holdings.
The filing documents a common pattern: exercise of vested employee options followed by an immediate sale of the same number of shares. The exercise price is $101.87 and the weighted-average sale price was $176.9067, indicating a realized gross spread per share of $75.0367 based on reported numbers. Direct beneficial ownership after the transactions is 14,000 shares, with substantial indirect holdings retained via SLAT (68,835) and the 401(k) fund (2,145). No new derivative holdings remain following the reported exercise. This is a disclosure of insider liquidity activity rather than an operational or governance event.
TL;DR: Proper Section 16 reporting of option exercise and sale; filing appears complete and signed via attorney-in-fact.
The Form 4 shows timely reporting of an exercise and sale executed on 08/15/2025 and filed with a signature dated 08/18/2025. Indirect holdings are clearly identified, including a spousal lifetime access trust and 401(k) plan shares, which helps clarify potential conflicts and control lines. The explanation discloses the price range for the sales and the filing states availability of detailed trade-level information upon request, supporting transparency. This filing is a routine insider disclosure with no governance actions reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Options (Right to Buy) | 16,820 | $101.87 | $1.71M |
| Exercise | Common Stock | 16,820 | $101.87 | $1.71M |
| Sale | Common Stock | 16,820 | $176.9067 | $2.98M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This transaction was executed in multiple trades at prices ranging from $176.87 to $177.015. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Held in a spousal lifetime access trust, of which the reporting person's spouse is the trustee and beneficiary. Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2025). Vested and exercisable one day after the third anniversary of the date of the grant.
